Non-Alcoholic Fatty Liver Disease: Study of Prevalence and Association with Type II Diabetes, Obesity and Dyslipidemia

Meenakshi Sidhar, Vevek Rana, Sandeepa .

Abstract


The spectrum of NAFLD ranges from mild steatosis to steatohepatitis with chances of progression to endstage liver disease and hepatocellular carcinoma. Prevalence of NAFLD varies in literature due to difference in methodologies used by various investigators in the past.

This study was conducted in the department of Medicine and Pathology. This study was done to find out the prevalence of hepatic steatosis in non-alcoholic asymptomatic adults, presenting with hepatomegaly or unexplained elevation of liver enzymes with special reference to non-alcoholic steatohepatitis The study also included study of prevalence of well-known risk factors like diabetes, dyslipidemia and obesity associated with NAFLD in Indian population. This was a prospective study and cases were selected from OPD and IPD by random selection, aged between 20 and 75 years, who presented with hepatomegaly along with asymptomatic liver enzymes derangements or ultrasound suggestive of fatty liver in the absence of history of alcohol intake. Out of 500 patients who agreed to participate in the study, 284 were males and 216 females. A total of 110 cases were found to have fatty liver on the basis of USG report, of which 75
cases were found attributed to NAFLD. Diabetes was seen in 32 cases out of these 75 patients, 43 subjects had dyslipidemia, 48.67% cases showed elevated aminotransferases level. Liver biopsy was performed in 25 patients and 16% cases showed steatosis, 32% cases showed steatohepatitis and 4% cases showed cirrhosis.


Keywords


Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), Diabetes, Obesity, Dyslipidemia, Metabolic syndrome

Full Text:

PDF

References


Falck-Ytter Y, Younossi ZM, Marchesinin G et al. Clinical

features and natural history of non-alcoholic steatosis

syndromes. Semin Liver Dis 2001; 21: 17: 17-26.

Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic

steatohepatitis: Summary of an AASLD Single topic

conference. Hepatology 2003; 37: 1202-19.

Third Report of the National Cholesterol Education

Program (NCEP) Expert Panel on Detection, Evaluation,

and Treatment of High Blood Cholesterol in Adults

(Adult Treatment Panel III) final report. Circulation2002; 106: 17: 3143-3421.

Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and

management of the metabolic syndrome: An American

Heart Association/National Heart, Lung, and Blood

Institute Scientific Statement. Circulation 2005; 112:

-52.

Nonmura A, Ussitupa M, Usours M et al. Clinico

pathological study of alcohol like liver disease in nonalcoholic

steatohepatits and fibrosis. Gastroenterol

; 27(4): 521-28.

Lonardo A, Bellini M, Tartoni P. The bright liver syndrome

.prevalence and determinants of a bright liver pattern.

Ital Gastroenterol Hepatol 1997; 29: 351-56.

Bellantani S, Saccoccio G, Masutti F et al. Prevalence

of and risk factors for hepatic steatosis in northern

Italy. Ann intern Med 2000; 132: 112-17.

Powell EE, Cooksley WG, Hanson R et al. The natural

history of non-alcoholic steatohepatits: A follow up

study of 42 patients for up to 21 years. Hepatology

; 11: 74-80.

Kim D, Touris A, Kim WR. Non-alcoholic fatty liver

disease and metabolic syndrome. Clin Liver Disease

Feb; 22(1).

Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver

disease review: Diagnosis, treatment, and outcomes.

Gastrenterol Hepatol 2015; 13: 2062-70.

Singh SP, Nayak S, Swain M et al. Prevalence of nonalcoholic

fatty liver disease in coastal eastern India: A

preliminary ultrasonography survey. Trop Gastroenterol

Apr-Jun; 25(2): 76-79.

Jonathan M. Hazlehurst, Conor Woods, Jeremy W.

Tomlinson. Non-alcoholic fatty liver disease and

diabetes. Metabolism 2016 Aug.

Tilg H, Moschen AR, Roden M. NAFLD and diabetes

mellitus. Nat Rev Gastroenterol Hepatol 2017 Jan;

(1): 32-42.

Ong JP, Elariny H, Collantes R et al. Predictors of

non-alcoholic steatohepatitis and advanced fibrosis

in morbidly obese patients. Obes Surg 2005; 15(3):

-15.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 International Journal of Preventive, Curative & Community Medicine (ISSN: 2454-325X)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.